SCHEMBL2163400

SCHEMBL2163400

N#CC(O)c1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
CES2 O00748 2/20 0.44
CES1 P23141 2/20 0.44
CYP3A4 P08684 6/20 0.37
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
GAA P10253 2/20 0.36
CNR2 P34972 1/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GFER P55789 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
EEF2K O00418 1/20 0.35
CCR1 P32246 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
CYP2D6 P10635 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495437 1.00 TSHR (0.50) TSHRCES2CES1CYP3A4IDO1
SCHEMBL13937393 0.84 TSHR (0.61) TSHRGAAALDH1A1MEN1KMT2A
SCHEMBL27263318 0.83 CES2 (0.47) TSHRCES2CES1GAAALDH1A1
SCHEMBL1199403 0.80 HTR1A (0.41) TSHRALDH1A1MEN1KMT2ASLC6A2
SCHEMBL8943608 0.78 CES2 (0.48) CES2CES1CYP3A4IDO1TDO2
SCHEMBL10548284 0.78 CES2 (0.44) CES2CES1CYP3A4IDO1TDO2
SCHEMBL29413776 0.78 CES2 (0.44) CES2CES1CYP3A4IDO1TDO2
SCHEMBL7199994 0.78 CES2 (0.44) CES2CES1CYP3A4IDO1TDO2
SCHEMBL11305915 0.76 CXCL8 (0.38) TSHRCES2CES1SLC6A2SLC6A4
SCHEMBL11602791 0.76 CES2 (0.54) CES2CES1CYP3A4IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2465929-B1 R-HNL random variants and their use for preparing optically pure, sterically hindered cyanohydrins DSM IP ASSETS BV (NL) 2015-12-02 EP disclosed
US-8846366-B2 R-hydroxynitrile lyase (R-HNL) random variants and their use for preparing optically pure, sterically hindered cyanohydrins DSM IP ASSETS BV (NL) 2014-09-30 US disclosed
EP-2092060-B1 R-HNL RANDOM VARIANTS AND THEIR USE FOR PREPARING OPTICALLY PURE, STERICALLY HINDERED CYANOHYDRINS DSM IP ASSETS BV (NL) 2014-01-22 EP disclosed
EP-2465929-A1 R-HNL random variants and their use for preparing optically pure, sterically hindered cyanohydrins DSM IP Assets B.V. (NL) 2012-06-20 EP disclosed
US-7985572-B2 Modified nitrilases and their use in methods for the production of carboxylic acids BASF SE (DE) 2011-07-26 US disclosed
US-20100228033-A1 METHOD OF MANUFACTURING 5-[2-CYCLOPROPYL-1-(2-FLUOROPHENYL)-2-OXOETHYL]-4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDIN-2-YL ACETATE (PRASUGREL) ZENTIVA K.S. (CZ) 2010-09-09 US disclosed
US-20100143986-A1 R-HNL RANDOM VARIANTS AND THEIR USE FOR PREPARING OPTICALLY PURE, STERICALLY HINDERED CYANOHYDRINS DSM IP ASSETS BV (NL) 2010-06-10 US disclosed
EP-2092060-A1 R-HNL RANDOM VARIANTS AND THEIR USE FOR PREPARING OPTICALLY PURE, STERICALLY HINDERED CYANOHYDRINS DSMIP Assets B.V. (NL) 2009-08-26 EP disclosed
EP-1599584-B1 MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS BASF SE (DE) 2009-07-01 EP disclosed
WO-2008071695-A1 R-HNL RANDOM VARIANTS AND THEIR USE FOR PREPARING OPTICALLY PURE, STERICALLY HINDERED CYANOHYDRINS DSM IP ASSETS BV (NL) 2008-06-19 WO disclosed
US-20060259999-A1 Modified nitrilases and their use in methods for the production of carboxylic acids BASF AKTIENGESELLSCHAFT (DE) 2006-11-16 US disclosed
EP-1599584-A1 MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS BASF AKTIENGESELLSCHAFT (DE) 2005-11-30 EP disclosed
WO-2004090124-A2 SEQUENCES ENCODING S-HYDROXYNITRIL LYASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CYANOHYDRINS BASF AKTIENGESELLSCHAFT (DE) 2004-10-21 WO disclosed
WO-2004076655-A1 MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS BASF AKTIENGESELLSCHAFT (DE) 2004-09-10 WO disclosed
CN-1111162-C Artemisinin derivatives, method for preparation thereof and pharmaceutical compositions containing the same SHANGHAI INST OF MATERIAL MEDI (CN) 2003-06-11 CN disclosed
US-6307068-B1 TREATING OR IN PREVENTING CANCER. ADIR ET COMPAGNIE (FR) 2001-10-23 US disclosed
EP-1086107-A1 ARTEMISININ DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2001-03-28 EP disclosed
CN-1243879-A Chiral cyanohydrin compound and its derivatives and preparing process SHANGHAI INST ORGANIC CHEM (CN) 2000-02-09 CN disclosed
WO-1999065914-A1 ARTEMISININ DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME SHANGHAI INSTITUTE OF MATERIA MEDICA (CN) 1999-12-23 WO disclosed
US-5994359-A PESTICIDES, FUNGICIDES BASF AKTIENGESELLSCHAFT (DE) 1999-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228033-A1 METHOD OF MANUFACTURING 5-[2-CYCLOPROPYL-1-(2-FLUOROPHENYL)-2-OXOETHYL]-4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDIN-2-YL ACETATE (PRASUGREL) PFAS, CYP2B6, CYP3A5 TSHR 3786/4885CES2 741/4885CES1 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.